We integrated quantitative proteomics and activity-based protein profiling (ABPP) approach to systematically elucidate the involved pathways and the covalent targets of natural products.
Here, by state-of-the-art mass spectrometry-based quantitative proteomic technology, we systematically screened the potential neo-substrates of a novel thalidomide derived cereblon modulator CC-885.
